Title |
Intervention | NCT ID | Sponsor | Status |
|---|---|---|---|---|
| Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and... | Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Ondansetron Hydrochloride, Palonosetron Hydrochloride, Placebo | NCT03578081 | Alliance for Clinical Trials in Oncology | Active, not recruiting |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer... | Megestrol Acetate, Olanzapine, Questionnaire Administration | NCT04939090 | Alliance for Clinical Trials in Oncology | Recruiting |
| Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by... | Laboratory Biomarker Analysis, Nutritional Intervention, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration | NCT03757949 | Southwest Oncology Group | Recruiting |
| NR in Chemo-induced Peripheral Neuropathy | Nicotinamide Riboside | NCT03642990 | Donna Hammond, PhD | Recruiting |
| Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III... | Nilotinib, Nilotinib Hydrochloride Monohydrate, Paclitaxel, Placebo, Questionnaire Administration | NCT04205903 | Ohio State University Comprehensive Cancer Center | Recruiting |
| New Assessment System in Measuring Symptom Distress in Cancer Patients | Interview, Quality-of-Life Assessment, Questionnaire Administration | NCT00505245 | M.D. Anderson Cancer Center | Recruiting |
| Neuropsychological and Behavioral Testing in Younger Patients With Cancer | Cognitive Assessment, Quality-of-Life Assessment | NCT00772200 | Children's Oncology Group | Recruiting |
| Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or... | Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment | NCT03367572 | University of Rochester NCORP Research Base | Recruiting |
| Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure | NCT02636582 | National Cancer Institute (NCI) | Active, not recruiting |
| NCI COVID-19 in Cancer Patients, NCCAPS Study | Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration | NCT04387656 | National Cancer Institute (NCI) | Active, not recruiting |
Why I Joined a Clinical Trial
Hi, my name is Raffaellina and [am here] thanks to the European Institute of Oncology and to the research! I am 76 years old and I have been diagnosed [with] breast cancer. I have chosen to participate into a clinical trial because of the clear and accurate explanation of my options and future perspectives and for the confidence in research transmitted by the Team I felt as a” human being” and not as a “number”, and this feeling has not changed afterwards. I was so scared about my future, but when the team proposed me to participate in the study, I have accepted it with enthusiasm. No adverse event occurred, and moreover, I have experienced benefit that impacted the definitive surgery. We need to trust and support clinical research!